NASDAQ:SCLX Scilex Q3 2026 Earnings Date & Estimates $1.25 -0.18 (-12.59%) Closing price 04:00 PM EasternExtended Trading$1.25 +0.00 (+0.40%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Scilex is estimated to report Q3 2026 earnings on Wednesday, December 2, 2026, before market opens. The conference call is scheduled for November 27, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateDecember 2, 2026TimeBefore Market OpensConference Call DateNovember 27, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Scilex in Q3 2026Scilex is expected to post earnings of -$0.0756 per share on revenue of $17 million. In the same quarter a year earlier Scilex reported -$22.17 per share on revenue of $10.56 million. Scilex last reported on August 14, 2026, posting -$16.65 per share and missing the -$0.1813 consensus estimate. Scilex has beaten the consensus EPS estimate in 1 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.0756Expected Revenue$17 millionPrior-Year EPS-$22.17Prior-Year Revenue$10.56 millionExpected Revenue Growth+61.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$16.65 (Missed by -$16.4687)Last Quarter Revenue$7.64 millionEPS Beat Rate1 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Scilex Q3 2026 Earnings FAQ When does Scilex report Q3 2026 earnings? Scilex (NASDAQ:SCLX) is estimated to report Q3 2026 earnings on Wednesday, December 2, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Scilex's Q3 2026 earnings call? Scilex's Q3 2026 earnings conference call is scheduled for Friday, November 27, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Scilex? Analysts expect Scilex to post earnings of -$0.0756 per share for Q3 2026. How much revenue is Scilex expected to report? The consensus revenue estimate for Scilex is $17 million for Q3 2026. Scilex Earnings HeadlinesScilex (NASDAQ:SCLX) Stock Price Down 8.3% - Here's WhyNovember 14 at 3:22 AM | americanbankingnews.comDatavault Stock (DVLT) Crashes Almost 50% Over $150 Million Bitcoin Issue Before Rising 22% TodayOctober 29, 2026 | tipranks.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 16 at 1:00 AM | Behind the Markets (Ad)Datavault AI Stock Crashes — Financials Cannot Be Trusted: What You Need to KnowOctober 27, 2026 | benzinga.comScilex Expands Credit Facility Support for Vivasor AffiliateSeptember 29, 2026 | tipranks.comScilex Establishes $20 Million Credit Facility for VivasorAugust 12, 2026 | tipranks.comSee More Scilex Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email. Email Address About ScilexScilex (NASDAQ:SCLX) is a biopharmaceutical company focused on developing and commercializing treatments for pain and related conditions. Its portfolio includes therapies designed to offer alternatives to conventional pain-management approaches. Its marketed products include ZTlido, a topical lidocaine system for pain associated with postherpetic neuralgia; Elyxyb, an oral celecoxib solution for acute migraine in adults; and GLOPERBA, an oral colchicine solution for preventing gout flares in adults. The company has also worked on investigational pain treatments, which are distinct from its approved products. Scilex’s commercial operations are focused primarily on the United States. The company became publicly traded in 2022 through a business combination with Vickers Vantage Corp. I.View Scilex ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.